<DOC>
	<DOC>NCT00035971</DOC>
	<brief_summary>The purpose of this study is to determine how treatment with raloxifene compares to treatment with alendronate in postmenopausal women with osteoporosis on the chance of experiencing fractures</brief_summary>
	<brief_title>EVA: Evista Alendronate Comparison</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<mesh_term>Raloxifene Hydrochloride</mesh_term>
	<criteria>Inclusion Criteria 5080 years of age, inclusive 2 years since last menses Dx femoral neck osteoporosis No vertebral fractures Exclusion Criteria Poor candidate for study drugs Hx of diseases affecting bone metabolism Hx of breast/estrogendependent cancer Current use of osteoporosis drug therapy Hx/high risk of VTE</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2006</verification_date>
</DOC>